Liu Zhuangkai, Xu Hong, Li Xiang, Zhang Ruishan, Bai Jinghui, Zhang Xinfeng
Department of Breast Cancer, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Dadong District, Shenyang, Liaoning, China.
Department of Internal Medicine, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Dadong District, Shenyang, Liaoning, China.
Arch Med Sci. 2020 Feb 4;19(4):1099-1107. doi: 10.5114/aoms.2020.92869. eCollection 2023.
Recent studies have proved the diverse roles of miRs in different cancer-related processes. This study was undertaken to determine the therapeutic implications of miR-325-3p in breast cancer.
Expression analysis was carried out by qRT-PCR. Transfections were performed by Lipofectamine 2000 reagent. MTT assay was used for cell viability. Transwell assays were used for cell migration and invasion. Western blot analysis was used for protein expression analysis.
Gene expression analysis revealed miR-325 to be significantly suppressed in breast cancer tissues and cell lines. Nonetheless, ectopic expression of miR-325 resulted in suppression of the growth and colony development potential of the SK-BR-3 and CAMA-1 cells. Transwell assays showed that miR-325 overexpression also resulted in the decline of the migration and invasion of the SK-BR-3 and CAMA-1 cells. Bioinformatic analysis showed that miR-325 targets lipocalin 15 (LNC15) in breast cancer cells. LNC15 was also overexpressed in the breast cancer tissues and cell lines. However, overexpression of miR-325 caused a significant decline in the LNC15 expression in SK-BR-3 cells. Additionally, silencing of LNC15 resulted in inhibition of the growth, migration and invasion of the SK-BR-3 cells. Rescue assay showed that overexpression of LNC15 could promote the growth, migration and invasion of the miR-325 overexpressing effects.
Taken together, the evidence shows that miR-325 acts as a tumor suppressor in breast cancer and may be used in the treatment of breast cancer.
最近的研究已证实微小RNA（miR）在不同癌症相关过程中具有多种作用。本研究旨在确定miR-325-3p在乳腺癌中的治疗意义。
通过qRT-PCR进行表达分析。使用Lipofectamine 2000试剂进行转染。MTT法用于检测细胞活力。Transwell实验用于检测细胞迁移和侵袭。蛋白质免疫印迹分析用于蛋白质表达分析。
基因表达分析显示，miR-325在乳腺癌组织和细胞系中显著下调。然而，miR-325的异位表达导致SK-BR-3和CAMA-1细胞的生长和集落形成能力受到抑制。Transwell实验表明，miR-325过表达还导致SK-BR-3和CAMA-1细胞的迁移和侵袭能力下降。生物信息学分析表明，miR-325在乳腺癌细胞中靶向脂质运载蛋白15（LNC15）。LNC15在乳腺癌组织和细胞系中也过表达。然而，miR-325过表达导致SK-BR-3细胞中LNC15表达显著下降。此外，沉默LNC15可抑制SK-BR-3细胞的生长、迁移和侵袭。挽救实验表明，LNC15过表达可促进miR-325过表达效应的生长、迁移和侵袭。
综上所述，证据表明miR-325在乳腺癌中起肿瘤抑制作用，可能用于乳腺癌的治疗。
